#1 out of 3176.4K est. views83.33%
health9h ago
Millions of breast cancer patients could avoid chemotherapy with new genome test
- The Optima trial tracked over 4,400 patients and used the Prosigna genomic test to guide treatment decisions.
- Low Prosigna scores (≤60) correlated with similar outcomes whether chemotherapy was given or not.
- Five-year survival and recurrence-free rates remained high without chemotherapy for low-score patients.
- Experts say results support reducing chemotherapy use for hormone-sensitive breast cancer.
- Researchers call Optima a robust, practice-changing study for personalized cancer care.
- Experts caution more research is needed to confirm benefits for men and younger patients.
- The Optima trial involved hormone-sensitive breast cancer patients after initial surgery.
- Low-score patients received hormone therapy alone rather than chemotherapy.
- Outcomes for low-score patients were comparable to those who had chemotherapy.
- The study highlights the potential for more personalized, targeted cancer care.
Vote 0


